<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775173</url>
  </required_header>
  <id_info>
    <org_study_id>2021-217</org_study_id>
    <nct_id>NCT04775173</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.</brief_title>
  <official_title>Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of different concentration&#xD;
      gradients of sirolimus in the treatment of Kaposiform hemangioendothelioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kaposiform hemangioendothelioma (KHE) is a rare aggressive vascular neoplasm that occurs&#xD;
      predominantly in infancy or early childhood, with an incidence of approximately 0.71/100,000.&#xD;
      Currently, sirolimus is a promising treatment modality for KHE. Most scholars consider&#xD;
      sirolimus blood concentration of 5-15 ng/ml to be an effective therapeutic concentration.&#xD;
&#xD;
      However, long-term higher dose sirolimus treatment can cause some common complications such&#xD;
      as oral mucositis which affects the quality of life of the patient. Finer control of the&#xD;
      plasma concentration of sirolimus may contribute to the efficacy of treatment and reduce the&#xD;
      incidence of complications. Therefore, we conducted this study to find out whether an early&#xD;
      reduction in sirolimus dose would benefit the prognosis of the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2021</start_date>
  <completion_date type="Anticipated">August 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes in KHE volume</measure>
    <time_frame>Baseline, 3, 6, and 12 months</time_frame>
    <description>Response to therapy was measured by volumetric magnetic resonance imaging (MRI) analyses were performed at baseline and 6 and 12 months after treatment and were independently assessed by 2 radiologists. Changes in KHE size were classified as further growth (increase of ≥10%), no change (&lt;10% increase and &lt;10% decrease), partial involution (decrease of ≥10% and &lt;75%), nearly complete involution (decrease of ≥75% and &lt;100%), or complete involution (100%).&#xD;
Photographs of the mixed KHE were taken at months 0, 6 and 12 by a medical photographer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of platelet counts</measure>
    <time_frame>Baseline, 1, 3, 6, and 12 months</time_frame>
    <description>Platelet counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of fibrinogen levels</measure>
    <time_frame>Baseline, 1, 3, 6, and 12 months</time_frame>
    <description>Fibrinogen levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) in patients</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQLTM) 4.0 Genetic Core Infant Scales (&lt;2 years) or Pediatric Quality of Life Inventory (PedsQLTM) 4.0 Genetic Core Scales (2-18 years) were used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the patient's musculoskeletal complication.</measure>
    <time_frame>Baseline, 3, 6, and 12 months</time_frame>
    <description>The severity of musculoskeletal complication was scored by using a 4-point scale: 1, asymptomatic or mild symptoms, clinical or diagnostic observations only; 2, moderate symptoms, limiting age-appropriate instrumental activities of daily living; 3, severe or medically significant symptoms, disabling or limiting self-care activities of daily living; and 4, life-threatening consequences, with urgent intervention indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of adverse events (e.g. gastrointestinal disorders, blood and lymphatic system disorders, metabolic disorders or other abnormal laboratory results, skin disorders and general disorders, etc.) collected by investigator and reported by parents. All adverse events were collected and graded according to Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4.0). The causality of the adverse event was determined by the multidisciplinary staff and was classified as definitively not related, probably not related, possibly related, probably related, or definitively related. Any dose reductions, interruptions, or cessations enacted at the discretion of the investigators were recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Kaposiform Hemangioendothelioma</condition>
  <arm_group>
    <arm_group_label>Low dose of sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus In the first 6 months, the plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose; then in the next 6 months, the plasma trough concentration of sirolimus is maintained within the range of 3-5 ng/ml by adjusting sirolimus dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular dose of sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus The plasma trough concentration of sirolimus is maintained within the range of 10-15 ng/ml by adjusting sirolimus dose, for 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Use of different doses of the same drug</description>
    <arm_group_label>Low dose of sirolimus</arm_group_label>
    <arm_group_label>Regular dose of sirolimus</arm_group_label>
    <other_name>Rapamycin</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Presenting a KHE with the following characteristics:&#xD;
&#xD;
          1. Clinical features and histological findings consistent with progressive,&#xD;
             non-resectable KHE.&#xD;
&#xD;
          2. Patients must be 0 - 18 years of age at the time of study entry.&#xD;
&#xD;
          3. Adequate liver function: a. Total bilirubin less than or equal to 1.5 x upper limit of&#xD;
             normal (ULN) for age, and; b. ALT and AST less than or equal to 2.5 x upper limit&#xD;
             normal (ULN) for age.&#xD;
&#xD;
          4. Adequate renal function: a. 0-5 years of age maximum serum creatinine (mg/dL) of 0.8;&#xD;
             b. 6-10 years of age maximum serum creatinine (mg/dL) of 1.0; c. 11-15 years of age&#xD;
             maximum serum creatinine (mg/dL) of 1.2; d. 16-18 years of age maximum serum&#xD;
             creatinine (mg/dL) of 1.5.&#xD;
&#xD;
          5. Adequate bone marrow function: Absolute Neutrophil Count (ANC) greater than or equal&#xD;
             to 1 x 10 to the ninth/Liter.&#xD;
&#xD;
          6. Consent of parents (or the person having parental authority in families): Signed and&#xD;
             dated written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergy to sirolimus or other rapamycin analogues.&#xD;
&#xD;
          2. Any known evidence of significant local or systemic uncontrolled infection, defined as&#xD;
             receiving intravenous antibiotics at the time of randomization.&#xD;
&#xD;
          3. Patients must not be known to be Human Immunodeficiency Virus positive or known&#xD;
             immunodeficiency. Testing is not required unless a condition is suspected.&#xD;
&#xD;
          4. Other concurrent severe and/or uncontrolled medical disease which could compromise&#xD;
             participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension,&#xD;
             severe malnutrition, chronic liver or renal disease, active upper gastrointestinal&#xD;
             tract ulceration).&#xD;
&#xD;
          5. Impairment of gastrointestinal function or chronic gastrointestinal disease that may&#xD;
             significantly alter the absorption of sirolimus.&#xD;
&#xD;
          6. Patients who have a history of malignancy.&#xD;
&#xD;
          7. Patients with an inability to participate or to follow the study treatment and&#xD;
             assessment plan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Ji, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Ji, MD, PhD</last_name>
    <phone>86 28 85423453</phone>
    <email>jijiyuanyuan@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Siyuan Chen, MD, PhD</last_name>
    <phone>86 28 85422215</phone>
    <email>siy_chen@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Ji, MD, PhD</last_name>
      <phone>+86 28 85423453</phone>
      <email>jijiyuanyuan@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Siyuan Chen, MD, PhD</last_name>
      <phone>+862885422215</phone>
      <email>siy_chen@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yi Ji, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jiangyuan Zhou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaiying Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tong Qiu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xue Gong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ji Y, Chen S, Yang K, Xia C, Li L. Kaposiform hemangioendothelioma: current knowledge and future perspectives. Orphanet J Rare Dis. 2020 Feb 3;15(1):39. doi: 10.1186/s13023-020-1320-1. Review.</citation>
    <PMID>32014025</PMID>
  </results_reference>
  <results_reference>
    <citation>Ji Y, Chen S, Xiang B, Li K, Xu Z, Yao W, Lu G, Liu X, Xia C, Wang Q, Li Y, Wang C, Yang K, Yang G, Tang X, Xu T, Wu H. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study. Int J Cancer. 2017 Aug 15;141(4):848-855. doi: 10.1002/ijc.30775. Epub 2017 May 26.</citation>
    <PMID>28486787</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang G, Chen H, Gao Y, Liu Y, Wang J, Liu XY. Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon: a retrospective cohort study. Br J Dermatol. 2018 May;178(5):1213-1214. doi: 10.1111/bjd.16400. Epub 2018 Mar 25.</citation>
    <PMID>29388191</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang Z, Yao W, Sun H, Dong K, Ma Y, Chen L, Zheng S, Li K. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up. J Dermatol. 2019 Nov;46(11):956-961. doi: 10.1111/1346-8138.15076. Epub 2019 Sep 5.</citation>
    <PMID>31489702</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnson AB, Richter GT. Vascular Anomalies. Clin Perinatol. 2018 Dec;45(4):737-749. doi: 10.1016/j.clp.2018.07.010. Epub 2018 Sep 18. Review.</citation>
    <PMID>30396415</PMID>
  </results_reference>
  <results_reference>
    <citation>Adams DM, Ricci KW. Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options. Hematol Oncol Clin North Am. 2019 Jun;33(3):455-470. doi: 10.1016/j.hoc.2019.01.011. Review.</citation>
    <PMID>31030813</PMID>
  </results_reference>
  <results_reference>
    <citation>Drolet BA, Trenor CC 3rd, Brandão LR, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, Blei F, David M, Elluru R, Frieden IJ, Friedlander SF, Iacobas I, Jensen JN, King DM, Lee MT, Nelson S, Patel M, Pope E, Powell J, Seefeldt M, Siegel DH, Kelly M, Adams DM. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr. 2013 Jul;163(1):285-91. doi: 10.1016/j.jpeds.2013.03.080.</citation>
    <PMID>23796341</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Yi Ji</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Kaposiform Hemangioendothelioma</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Hemangioendothelioma</mesh_term>
    <mesh_term>Kasabach-Merritt Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

